Katie is Managing Director at the JDRF T1D Fund, an evergreen, Boston-based venture philanthropy fund launched in 2017, focused on accelerating life-changing solutions to cure, prevent and treat type 1 diabetes (T1D) through equity investments. She currently serves on the board of DiogenX, Veralox, i2O, Biolinq, Seraxis, Enthera, GentiBio, and Zag Bio and has previously served on the boards of Pandion (sold to Merck), Protomer (sold to Eli Lilly), and Inversago (sold to Novo Nordisk).Katie has been a life-sciences and medical device-oriented venture capital investor in the US and Europe for over a decade, previously with Endeavour Vision, a Geneva-based medical devices and digital health fund, and at Sofinnova Partners, Paris, a leading life sciences fund, investing in medical technologies. In her prior roles she served on several medical device boards including of ReCor Medical (sold to Otsuka Holdings), Shockwave Medical (NASDAQ: SWAV), and RefleXion Medical.Prior to VC, Katie held roles in Business Development, Sales and Marketing at Medtronic in the Cardiac and Vascular businesses.
